# Monopar Therapeutics > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Monopar Therapeutics). ## Overview Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers. Its pipeline centers on ALXN1840, a late-stage Wilson disease asset, and MNPR-101 radiopharmaceutical programs for imaging and treating solid tumors. ## Products & services • ALXN1840 (tiomolybdate choline) for Wilson disease • MNPR-101-Zr imaging and dosimetry agent • MNPR-101-Lu therapeutic radiopharmaceutical • MNPR-101-Ac225 preclinical therapeutic candidate • In-licensing and development of novel drug candidates • Regulatory, clinical, and IP development for rare disease and oncology assets - **Wilson disease therapy** (35%) — Late-stage investigational treatment for Wilson disease, centered on ALXN1840. - **Radiopharmaceutical imaging** (25%) — MNPR-101-based diagnostic imaging and dosimetry programs for advanced cancers. - **Radiopharmaceutical therapeutics** (25%) — Therapeutic radioisotope programs designed to treat uPAR-expressing solid tumors. - **Preclinical pipeline and discovery** (10%) — Earlier-stage assets and internal R&D to expand the oncology pipeline. - **Licensing and development services** (5%) — In-licensing, collaboration, and regulatory development activities supporting the pipeline. - ALXN1840 (tiomolybdate choline) for Wilson disease - MNPR-101-Zr imaging and dosimetry agent - MNPR-101-Lu therapeutic radiopharmaceutical - MNPR-101-Ac225 preclinical therapeutic candidate - In-licensing and development of novel drug candidates - Regulatory, clinical, and IP development for rare disease and oncology assets ## Customers Monopar does not yet sell approved products, so its near-term customers are clinical investigators, trial sites, regulators, and collaboration partners rather than end-market patients. If approved, its commercial buyers would be physicians, hospitals, and specialty pharmacies treating Wilson disease or advanced cancer patients. The company also depends on licensors and strategic partners such as Alexion/AstraZeneca for asset access and development rights. - **Regulators and clinical trial ecosystem** (primary) — FDA, CROs, and trial sites that enable development and approval of ALXN1840 and MNPR-101 programs. - **Wilson disease treatment providers** (primary) — Specialist physicians and treatment centers that would prescribe ALXN1840 if approved. - **Advanced cancer care centers** (secondary) — Hospitals and oncology centers that could use MNPR-101 imaging or therapeutic agents. - **Strategic licensing partners** (primary) — Pharma partners that may out-license, co-develop, or commercialize assets with Monopar. - Clinical trial sites and investigators running ALXN1840 and MNPR-101 studies - Regulators such as the FDA for NDA review and approval - Hospitals and specialists treating Wilson disease if ALXN1840 is approved - Oncology centers that could use imaging or therapeutic radiopharmaceuticals - Licensing partners and collaborators that fund or share development risk ## Geography Monopar is headquartered in the United States and its development, financing, and clinical operations are primarily U.S.-based. The company’s programs are intended for U.S. regulatory approval first, though its management cites prior experience with FDA and EMA submissions and global commercialization. Geography matters mainly through U.S. clinical trial execution, FDA filing strategy, and potential future expansion into Europe or other markets. - Headquartered in the United States - Clinical trials and regulatory work are primarily U.S.-based - NDA filing is being prepared for the FDA - Potential future commercialization could expand beyond the U.S. - Management has prior FDA and EMA experience ## Strategy Monopar’s strategy is to advance a small number of high-value assets through late-stage development, starting with an NDA package for ALXN1840 in Wilson disease. It is also building a radiopharmaceutical platform around MNPR-101, aiming to create both diagnostic and therapeutic products for aggressive cancers. The company relies on in-licensing, clinical execution, and intellectual property protection to create optionality for partnering or commercialization. - **Prepare ALXN1840 NDA submission** (short-term) — Regulatory approval is the key value inflection point for the Wilson disease asset. - **Advance MNPR-101 radiopharmaceutical pipeline** (medium-term) — The imaging and therapeutic programs could create a second value driver in oncology. - **Preserve financing flexibility** (short-term) — As a pre-revenue biotech, Monopar must fund R&D until approval or partnering monetization. - File an NDA for ALXN1840 in Wilson disease - Advance MNPR-101 imaging and therapeutic radiopharmaceutical programs - Move MNPR-101-Ac225 from preclinical work into the clinic - Protect and expand intellectual property around core programs - Use partnering or licensing to fund development and commercialization ## Risks Monopar is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and access to capital before any product sales. The main risks are trial failure, delays in FDA review, IP disputes, and dilution or restrictive terms from future financing or partnering. Radiopharmaceutical development also carries manufacturing, safety, and competitive risks typical of oncology drug development. - **Clinical development failure or delay** [high] — Pipeline value depends on positive trial outcomes for ALXN1840 and MNPR-101 programs. - **Financing and dilution risk** [high] — The company has not generated product revenue and expects to fund operations externally. - **Regulatory approval risk** [high] — Commercialization depends on FDA approval of a late-stage rare disease asset and oncology candidates. - **Competition and market adoption risk** [medium] — Competing therapies could limit uptake or reduce the commercial potential of the pipeline. - **Manufacturing and supply chain risk** [medium] — Radiopharmaceutical and clinical supply chains are complex and must meet quality standards. - No product revenue yet; funding depends on capital markets and partners - Clinical trials may fail, delay, or produce inconclusive results - FDA approval risk is concentrated in ALXN1840 and radiopharmaceutical assets - IP protection is critical and may require costly defense or licensing payments - Future financing could dilute shareholders or force unfavorable deal terms ## Accounting The most important accounting judgments are clinical trial accruals, stock-based compensation, and fair-value impacts from financing activities. Because Monopar is pre-revenue, R&D and G&A expense timing can swing materially with trial progress, board compensation, legal costs, and equity awards. Investors should also watch how treasury investments and capital raises affect interest income, cash flow, and dilution. - **Clinical trial accruals** — Can cause quarter-to-quarter swings in R&D expense - **Stock-based compensation** — Can inflate non-cash operating expenses - **Treasury securities and interest income** — Affects net loss and liquidity presentation - **Equity financing and share issuance** — Changes share count and cash runway - Clinical trial accruals depend on estimated work completed by CROs and sites - R&D expense timing can shift with trial activity and site setup costs - Stock-based compensation materially affects G&A and board compensation - Treasury securities and financing activity affect interest income and cash flow - No product revenue yet, so expense recognition drives reported losses --- *Last updated: 2026-04-28T20:27:38.172794+00:00*